Skip to main content

Advertisement

Table 5 Treatment and outcome of PCR-confirmed influenza patients in Bavarian PICUs, 2010–2013. Data are shown by virus type/subtype (n = 47)a

From: Continued high incidence of children with severe influenza A(H1N1)pdm09 admitted to paediatric intensive care units in Germany during the first three post-pandemic influenza seasons, 2010/11–2012/13

  Influenza type/subtype Comparison of seasons
A(H1N1)pdm09c
Treatment All A A(H1N1)pdm09 A(H3N2) A (subtype n.a.) B S1 vs S3
  N = 47 N = 40 N = 32 N = 4 N = 4 N = 7 p-value*
Antiviral drugsb; n (%) 13 (27.7) 12 (30.0) 9 (28.1) 1 (25.0) 2 (50.0) 1 (14.3) 1.000
Antibiotics i.v.; n (%) 34 (72.3) 31 (77.5) 25 (78.1) 2 (50.0) 4 (100.0) 3 (42.9) 0.676
Antipyretics; n (%) 33 (70.2) 28 (70.0) 22 (68.8) 2 (50.0) 4 (100.0) 5 (71.4) 0.452
Catecholamines; n (%) 13 (27.7) 13 (32.5) 11 (34.4) 1 (25.0) 1 (25.0) 0 (0.0) 1.000
Inhalation therapy; n (%) 13 (27.7) 13 (32.5) 11 (34.4) 2 (50.0) 0 (0.0) 0 (0.0) 1.000
Oxygen; n (%) 31 (66.0) 28 (70.0) 20 (62.5) 4 (100.0) 4 (100.0.) 3 (42.9) 0.275
Intratracheal ventilation; n (%) 15 (31.9) 14 (35.0) 12 (37.5) 1 (25.0) 1 (25.0) 1 (14.3) 1.000
CPAP; n (%) 11 (23.4) 9 (22.5) 7 (21.9) 0 (0.0) 2 (50.0) 2 (28.6) 0.084
Other; n (%) 14 (29.8) 13 (32.5) 10 (31.3) 2 (50.0) 1 (25.0) 1 (14.3) 0.247
Outcome        
 Sequelae; n (%) 5 (10.6) 4 (10.0) 3 (9.4) 1 (25.0) 0 (0.0) 1 (14.3) 0.548
 Death; n (%) 5 (10.6) 5 (12.5) 5 (15.6) 0 (0.0) 0 (0.0) 0 (0.0) 1.000
  1. n.a. not available, vs versus, i.v. intravenous
  2. *Fisher’s Exact test or Mann–Whitney U-test, respectively
  3. aClinical data was not available for one influenza A(H1N1)pdm09 and three influenza B patients
  4. bOseltamivir (n = 8), oseltamivir plus acyclovir (n = 1), acyclovir (n = 3), gancyclovir plus valgancyclovir (n = 1)
  5. cComparison restricted to influenza A(H1N1)pdm09 patients from Season 1 (S1; Oct10–Sep 11; n = 18) and Season 3 (S3; Oct12–Sep 13; n = 13)